source
- Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increaseEntrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…
- Daraxonrasib shows 35% response rate in second‑line RAS‑mutated pancreatic cancerPhase 1/2 data from a monotherapy study of daraxonrasib in patients with RAS G12‑mutated pancreatic ductal adenocarcinoma reported an objective response rate of 35% when used as a second‑line treat…